ANIP vs COTY Comparison

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake.